BOULDER, Colo., April 2, 2026 /PRNewswire/ -- The novel, radiopaque, polymer-based embolic coil from Embolization, Inc., is demonstrating consistent success in its limited-market release, with use ...

Background A 48-year-old man with hypertrophic obstructive cardiomyopathy (HOCM) presented with palpitations, symptoms of medically refractory class II angina, and NYHA class II–III heart failure.

LONDON--(BUSINESS WIRE)--The global embolization coil market is expected to post a CAGR of close to 5% during the period 2019-2023, according to the latest market research report by Technavio.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Boston Scientific announced it received FDA 510(k) ...